Study Evaluating The Effects Of Oprelvekin On Cardiac Repolarization In Subjects With Chemotherapy Induced Thrombocytopenia

Inclusion Criteria: * Men and women must be 18 to 65 years of age, with nonmyeloid malignancies for whom oprelvekin is indicated. * At least one documented occasion of adequate hematologic recovery from previous or current chemotherapy. * Adequate renal and hepatic excretory function. Exclusion Criteria: * A marked baseline prolongation of QT/QTc interval (eg, repeated \[two out of three readings\] demonstration of a QTcF interval \>450 msec. * Additional risk factors for torsades de pointes including heart failure (subjects that have functional class III or IV congestive heart failure), hypokalemia, hypomagnesemia, or hypocalcemia. * A pace maker or defibrillator. * A history of LQTS, syncope, seizure, or the unexplained cardiac-related death of a family member at less than 30 years of age. * Requirement of concomitant prescription or non-prescription medications or dietary supplements that have a risk of causing torsades de pointes or prolonged QT/QTc interval.